Objective. To estimate an effect of cellex on the dynamics and time of speech functions recovery in the acute stage of ischemic stroke. Material and methods. A multicenter, randomized, double-blind, placebo controlled clinical study included 8 Russian clinical sites. Four hundred eighty patients were involved. During the standard base therapy, cellex (or placebo) was introduced subcutaneously in dose 0,1 mg once a day in the first 10 days from the beginning of hospitalization. Results and conclusion. The rapid and complete regress of aphasia, especially in cases of severe and middle to severe clinical course, was observed.